• Chakradhari Inampudi, Daniel Silverman, Marc A Simon, Peter J Leary, Kavita Sharma, Brian A Houston, Jean-Luc Vachiéry, Francois Haddad, and Ryan J Tedford.
• Division of Cardiology, Department of Medicine, Medical University of South Carolina, Charleston, SC.
• Chest. 2021 Dec 1; 160 (6): 223222462232-2246.

AbstractHeart failure with preserved ejection fraction (HFpEF) is the most common form of heart failure and frequently is associated with pulmonary hypertension (PH). HFpEF associated with PH may be difficult to distinguish from precapillary forms of PH, although this distinction is crucial because therapeutic pathways are divergent for the two conditions. A comprehensive and systematic approach using history, clinical examination, and noninvasive and invasive evaluation with and without provocative testing may be necessary for accurate diagnosis and phenotyping. After diagnosis, HFpEF associated with PH can be subdivided into isolated postcapillary pulmonary hypertension (IpcPH) and combined postcapillary and precapillary pulmonary hypertension (CpcPH) based on the presence or absence of elevated pulmonary vascular resistance. CpcPH portends a worse prognosis than IpcPH. Despite its association with reduced functional capacity and quality of life, heart failure hospitalizations, and higher mortality, therapeutic options focused on PH for HFpEF associated with PH remain limited. In this review, we aim to provide an updated overview on clinical definitions and hemodynamically characterized phenotypes of PH, pathophysiologic features, therapeutic strategies, and ongoing challenges in this patient population.Copyright © 2021 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.

14 keywords...

hide…